GEN Exclusives

More »

GEN Poll

More »
Jan 30, 2012

California Biopharma Forecast

California may still be called the Golden State, but its image among biotech and pharma startups has been tarnished. The financial squeeze has dried up sources of funding, plus the combination of federal and state red tape serves as a one-two punch. Nearly three-quarters (74.2%) of some 100 CEOs surveyed recently said their companies were forced to delay a research or development project in the last year. When asked why, more than two-thirds cited either lack of available financing, heavy-handed regulation, or both. As a result, some CEOs are looking at expanding overseas. How do you think California will fair?

What is your forecast over the next 12 months for startup biopharma companies trying to do business in California?

Sunny
 
  19.3%
Cloudy
 
  33.7%
Stormy
 
  36.1%
Undecided
 
  10.8%

More Polls » View Results »

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?